Loading...
Market
What will be the impact of Ozempic on the progression from prediabetes to type 2 diabetes in China by end of 2024?
2
Resolution / Starting Odds
Significant reduction • 25%
Moderate reduction • 25%
No change • 25%
Increase • 25%
Studies and reports from Chinese medical institutions and health organizations
Story
China Adopts Ozempic in Weight Loss Guidelines, British Heart Foundation Optimistic
Sep 3, 2024, 06:04 AM
New guidelines from a leading medical advisory body in China are incorporating 'miracle cure' medications such as Ozempic into weight loss treatments, potentially changing the lives of millions and boosting sales for drugmakers. Bryan Williams from the British Heart Foundation expressed optimism about Ozempic's potential to help with extreme weight loss and other conditions. Ozempic, originally developed to treat diabetes, has shown promise in aiding weight loss and reducing risks of cardiovascular issues. Recent studies indicate that semaglutide, the active ingredient in Ozempic, is effective in reducing the progression from prediabetes to type 2 diabetes. Despite the enthusiasm, experts urge caution, noting the need for long-term studies to fully understand the drug's effects. Additionally, new research has found no increased risk of mental health issues among users of semaglutide for weight loss.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
No significant change • 25%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
No new data released • 25%
Reduction below 20% • 25%
Reduction between 20% and 30% • 25%
Reduction above 30% • 25%
Yes • 50%
No • 50%
Significant reduction • 25%
Moderate reduction • 25%
No significant change • 25%
Increase in events • 25%
Confirms significant risk • 25%
No significant risk found • 25%
Inconclusive results • 25%
Study retracted • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%